Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis

AIMS : Fibroblast growth factor (FGF) 21, a key regulator of energy metabolism, is currently evaluated in humans for treatment of type 2 diabetes and non-alcoholic steatohepatitis. However, the effects of FGF21 on cardiovascular benefit, particularly on lipoprotein metabolism in relation to atheroge...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Cong, Schönke, Milena, Zhou, Enchen, Li, Zhuang, Kooijman, Sander, Boon, Mariëtte R, Larsson, Mikael, Wallenius, Kristina, Dekker, Niek, Barlind, Louise, Peng, Xiao-Rong, Wang, Yanan, Rensen, Patrick C N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803070/
https://www.ncbi.nlm.nih.gov/pubmed/33693480
http://dx.doi.org/10.1093/cvr/cvab076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803070/
https://www.ncbi.nlm.nih.gov/pubmed/33693480
http://dx.doi.org/10.1093/cvr/cvab076

Ejemplares similares